Compare EVAX & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVAX | PASG |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.4M | 28.3M |
| IPO Year | 2021 | 2020 |
| Metric | EVAX | PASG |
|---|---|---|
| Price | $3.36 | $8.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $12.33 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 76.2K | 52.1K |
| Earning Date | 03-31-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,650,000.00 | N/A |
| Revenue This Year | $128.77 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 132.17 | N/A |
| 52 Week Low | $1.20 | $5.12 |
| 52 Week High | $12.15 | $20.00 |
| Indicator | EVAX | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 37.50 | 36.92 |
| Support Level | $3.06 | $8.39 |
| Resistance Level | $3.66 | $10.12 |
| Average True Range (ATR) | 0.33 | 1.32 |
| MACD | 0.04 | -0.34 |
| Stochastic Oscillator | 33.26 | 9.20 |
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.